Working Together to Find a Cure     Print Page | Close Window

Press Release

Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference

NEW YORK and CLEVELAND, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that management will participate in the Jefferies 2018 London Healthcare Conference. To access the event via live webcast, please visit the investor section of Abeona’s website, www.abeonatherapeutics.com.

Jefferies 2018 London Healthcare Conference
Date: Thursday, November 15th at 10:40 AM GMT
Presenter: João Siffert, M.D., Chief Medical Officer, Head of Research & Development
Location: Waldorf Hilton, London, England
Webcast: http://wsw.com/webcast/jeff115/abeo/

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM™, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.

Investor Contact:
Christine Silverstein
SVP, Finance & Investor Relations
Abeona Therapeutics Inc.
+1 (646) 813-4707
csilverstein@abeonatherapeutics.com

Media Contact:
Scott Santiamo
Director, Corporate Communications
Abeona Therapeutics, Inc.
+1 (646) 813-4719
ssantiamo@abeonatherapeutics.com

Abeona Therapeutics.jpg

Abeona Therapeutics Inc.